ArticleClinical rheumatology2025
Enhanced co-expression of TIGIT and PD-1 on γδ T cells correlates with clinical features and laboratory parameters in patients with primary Sjögren's syndrome.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The role and function of CTLA-4 in Sjögren's syndrome.Frontiers in immunology · 2026Review
- Transcriptomic Analysis Reveals C-C Motif Chemokine Receptor 1 as a Critical Pathogenic Hub Linking Sjögren's Syndrome and Periodontitis.Current issues in molecular biology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe research aimed to assess the proportions of Gamma delta (γδ) T cells and the expression levels of CD226, ICOS, CD40L, OX40, TIGIT, LAG-3, Tim-3, and PD-1 on γδ T cells in the peripheral blood of patients diagnosed with primary Sjögren's syndrome (pSS), and to evaluate the clinical significance of these findings.
methodsUtilizing flow cytometry, we investigated the proportion of γδ T cells and the expression of CD226, ICOS, CD40L, OX40, TIGIT, LAG-3, PD-1, and Tim-3 on γδ T cells in 37 patients diagnosed with pSS and 28 healthy controls (HC). Moreover, we explored the potential associations between the proportion of γδ T cells, TIGIT + γδ T cells, PD-1 + γδ T cells, and TIGIT + PD-1 + γδ T cells with clinical symptoms and laboratory parameters.
resultsCompared to HC, patients with pSS showed a decreased proportion of γδ T cells, alongside an increased proportion of TIGIT + γδ T cells, PD-1 + γδ T cells, and TIGIT + PD-1 + γδ T cells (p < 0.01). Nevertheless, there were no statistically significant variations noted in the expression levels of CD226, ICOS, CD40L, Tim-3, LAG-3, and OX40 on γδ T cells between two groups (p > 0.05). Furthermore, γδ T cells demonstrated a declining trend in patients with clinical symptoms such as xerostomia, xerophthalmia, decayed teeth, and fatigue, as well as in those with high IgG levels and positivity for anti-SSB/La, anti-SSA/Ro60, and anti-SSA/Ro52. Conversely, TIGIT + γδ T cells, PD-1 + γδ T cells, and TIGIT + PD-1 + γδ T cells exhibited an increasing trend in these patient groups. In correlation analyses with IgG, ESR, CRP, C3, C4, IgA, RF, IgM, and ESSDAI, γδ T cells were observed to have a negative correlation with ESR, IgG and ESSDAI. TIGIT + γδ T cells demonstrated significant positive correlations with IgG, IgA, and ESSDAI. PD-1 + γδ T cells showed positive correlations with ESR, CRP, IgA, and ESSDAI. Furthermore, TIGIT + PD-1 + γδ T cells showed significant positive correlations with ESR, IgG, RF, IgA, and ESSDAI.
conclusionOur results indicated that patients with pSS exhibited a reduction in γδ T cells alongside elevated expression of TIGIT, PD-1, and their co-expression on γδ T cells. These changes were found to correlate with clinical symptoms and laboratory parameters, suggesting that γδ T cells, TIGIT + γδ T cells, PD-1 + γδ T cells, and especially TIGIT + PD-1 + γδ T cells could potentially serve as diagnostic biomarkers for pSS.
Indexed as
Identifiers
39856468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.